Investigators from Hackensack Meridian John Theurer Cancer Center (JTCC) will report research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
The meeting is the premier event for cancer professionals and takes place in Chicago from May 29 to June 2.
JTCC is part of the National Cancer Institute-designated Lombardi Comprehensive Cancer Center at Georgetown University.
Many of the studies focus on innovative therapies for blood cancers and novel immunotherapies. These are areas of expertise for John Theurer Cancer Center, New Jersey’s largest cancer center. The findings of these investigations have the potential to change the treatment and understanding of hematologic, solid tumors, melanoma, and other cancers.
It will present research from 11 studies on solid tumors, eight regarding hematologic malignancies, two on immunotherapy, one on melanoma, and four about models of care.
In April, Hackensack Meridian Health (HMH) announced its participation in a massive Phase 3 clinical trial to develop the first vaccine against Clostridioides difficile, commonly known as C. diff.
